Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
An individual associated with Ionis Pharmaceuticals has filed a notice of proposed sale of restricted securities under Rule 144. The filer plans to sell 9,191 shares of Ionis common stock through Morgan Stanley Smith Barney on the NASDAQ, with an indicated aggregate market value of $700,602.62 at the time of the notice. Ionis had 161,137,930 common shares outstanding when this notice was prepared.
The shares to be sold are common stock acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, described as compensation. The planned sale date is listed as 01/16/2026. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about Ionis Pharmaceuticals.
A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale under Rule 144 for 9,302 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/16/2026 and an aggregate market value of 709071.67.
The securities were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation, in the same amount of 9,302 shares. The filing notes that 161,137,930 shares of the issuer’s common stock were outstanding, providing context for the planned sale.
Ionis Pharmaceuticals filed a notice of proposed insider share sales under Rule 144. The filing covers 1,823 shares of common stock to be sold through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $138,963.60. The issuer reports 161,137,930 shares of common stock outstanding.
The shares to be sold were acquired as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation, with both the grant and payment dated 01/15/2026. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Ionis Pharmaceuticals’ operations.
Ionis Pharmaceuticals insider plans another stock sale under Rule 144. A holder has filed to sell 8,353 shares of Ionis common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $636,626.29. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation.
The notice also lists recent sales in the past three months for the same account holder. Shannon Devers sold 16,777 shares of common stock on 11/25/2025 for gross proceeds of $1,342,160.00, and 44,199 shares on 01/07/2026 for gross proceeds of $3,760,522.76 through Stifel Nicolaus & Company Inc. The filer represents that they are not aware of undisclosed material adverse information about Ionis.
Ionis Pharmaceuticals, Inc. reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA. These figures are unaudited, may be adjusted, and are being shared ahead of the company’s full financial results, which are planned for February 2026. The sales number gives an early view of TRYNGOLZA’s commercial performance in the U.S. market but does not represent the company’s complete 2025 financial picture.
Ionis Pharmaceuticals' EVP and Chief Human Resources Officer, Shannon L. Devers, reported a series of option exercises and share sales on January 7, 2026. Devers exercised several non-qualified stock options to acquire common stock at exercise prices of $32.60, $37.58, $52.87, and $56.78, then sold the resulting shares in market transactions. Blocks sold included 25,545 shares at a weighted average price of $85.36 and 9,264 shares at a weighted average price of $84.62, among other trades. After these transactions, Devers directly held 17,494 shares of Ionis common stock. The sales were made under a Rule 10b5-1 trading plan adopted on September 3, 2024.
Capital World Investors reports beneficial ownership of 17,961,299 shares of Ionis Pharmaceuticals, Inc. common stock, representing 11.1% of the class, based on 161,974,393 shares believed outstanding as of the event date. The firm has sole voting and dispositive power over all reported shares and no shared power. It certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ionis.
An affiliate of the issuer has filed a notice under Rule 144 to sell 9,390 shares of common stock through broker Stifel Nicolaus & Company on the Nasdaq market, with an aggregate market value of $795,117. The filing notes that 161,974,393 shares of the issuer’s common stock were outstanding at the time of the notice.
The shares to be sold were acquired from the issuer through stock option exercises on three dates in 2022, 2023, and 2024, all paid in cash. The person filing the notice previously sold 16,777 shares on 11/25/2025 for gross proceeds of $1,342,160 and 3,162 shares on 09/03/2025 for gross proceeds of $192,882. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Ionis Pharmaceuticals reported that partner GSK delivered positive results from two pivotal Phase 3 B-Well studies of bepirovirsen for chronic hepatitis B. The trials, which enrolled over 1,800 patients across 29 countries, met their primary endpoint and showed a statistically significant, clinically meaningful functional cure rate when bepirovirsen was added to standard of care versus standard of care alone, with an acceptable safety profile.
Chronic hepatitis B affects more than 250 million people worldwide and is a leading cause of liver cancer. If approved, bepirovirsen could become the first finite, six‑month therapeutic option and a backbone for future treatment strategies. Under its 2019 licensing agreement with GSK, Ionis is eligible to receive an additional $150 million in regulatory and sales milestone payments and tiered royalties of 10–12% on net sales of bepirovirsen.
Ionis Pharmaceuticals EVP Research Eric Swayze reported multiple stock option exercises and related share sales on 01/02/2026. He exercised options for 5,125 and 18,338 shares of common stock at an exercise price of $60.89 per share and sold the same numbers of shares at weighted average prices of $78.57 and $79.27, respectively, under a Rule 10b5-1 trading plan.
After these transactions, Swayze held 30,453 Ionis common shares directly and 256 shares indirectly through his son. He also received a new grant of non-qualified stock options for 19,350 shares at an exercise price of $79.67, vesting 25% on 01/02/2027 with the rest vesting in 36 monthly installments over three years, while his son received options for 150 shares on the same terms, reported as indirectly owned.